Recurrent ovarian cancer: use of contrast-enhanced CT and PET/CT to accurately localize tumor recurrence and to predict patients' survival.
about
Leptomeningeal carcinomatosis and bilateral internal auditory canal metastases from ovarian carcinoma.Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up.Diagnostic and prognostic evaluation of fluorodeoxyglucose positron emission tomography/computed tomography and its correlation with serum cancer antigen-125 (CA125) in a large cohort of ovarian cancer patientsDiagnosis and management of peritoneal metastases from ovarian cancer.Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery.Posttreatment FDG PET/CT in predicting survival of patients with ovarian carcinoma.The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancerMolecular Imaging of Ovarian CancerCorrelation of preoperative magnetic resonance imaging of peritoneal carcinomatosis and clinical outcome after peritonectomy and HIPEC after 3 years of follow-up: preliminary resultsMultimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent.An update on the role of PET/CT and PET/MRI in ovarian cancer.Role of preoperative MR imaging in the evaluation of patients with persistent or recurrent gynaecological malignancies before pelvic exenteration.Preoperative assessment of peritoneal carcinomatosis: intraindividual comparison of 18F-FDG PET/CT and MRI.Positron emission tomography-laparoscopy based method in the prediction of complete cytoreduction in platinum-sensitive recurrent ovarian cancer.Diagnostic value of positron emission tomography (PET) and PET/computed tomography in recurrent/metastatic ovarian cancer: A meta-analysis.
P2860
Q33638394-5758C29C-0142-4C8A-9918-EE9A8ACD6089Q35877090-51C62575-57BD-475B-B816-28ED7F53E43FQ36029023-702CFB06-CC1C-47B5-BCB3-D41DCC0A866EQ36128985-132A2A18-05F2-4F72-8CC3-5D3CC21DCDCEQ36132602-510A59A5-1C2D-4918-96A8-D06468B43494Q36923202-B6CECBD8-E0DC-437F-8A5D-71FA20B6C9EBQ37182860-E2ECCBF3-3AC8-4F0D-8E1D-ADD53A1FD69DQ37305724-FCAF0503-8CB1-4908-9B37-E26399D6A3FCQ37489783-EB6E7B11-93CE-456F-9626-057221A60FDAQ37526228-C3FD1A89-EE45-4C6D-BA11-80A488D259B1Q39127714-226EFD48-12CF-4161-90DD-8BD181A83244Q43725295-DBC87510-5BCE-47D3-8DA9-356C6B910ABFQ44076876-CF5F1317-B15C-49A0-9A56-2860941FF585Q51050471-8F4E2CE7-547B-4CBA-B091-3F70A8794DEBQ52953075-E00E322C-A69C-4CA5-B45B-0D45923E28B8
P2860
Recurrent ovarian cancer: use of contrast-enhanced CT and PET/CT to accurately localize tumor recurrence and to predict patients' survival.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Recurrent ovarian cancer: use ...... to predict patients' survival.
@en
Recurrent ovarian cancer: use ...... to predict patients' survival.
@nl
type
label
Recurrent ovarian cancer: use ...... to predict patients' survival.
@en
Recurrent ovarian cancer: use ...... to predict patients' survival.
@nl
prefLabel
Recurrent ovarian cancer: use ...... to predict patients' survival.
@en
Recurrent ovarian cancer: use ...... to predict patients' survival.
@nl
P2093
P2860
P356
P1433
P1476
Recurrent ovarian cancer: use ...... to predict patients' survival.
@en
P2093
Chaya S Moskowitz
Dennis S Chi
Masako Kataoka
Michelle A Collins
Neeta Pandit-Taskar
Nicole Ishill
Oleg Mironov
Steven Larson
Svetlana Mironov
P2860
P304
P356
10.1148/RADIOL.10092279
P407
P577
2010-08-09T00:00:00Z